Develops gene-editing treatments that fix single letters of DNA.
New: first time
Duquesne bought Beam Therapeutics for the first time between April and June: 153,600 shares, worth about $5 million. That’s already less than $1 of every $100 they have in stocks.
Mar 31
None
Jun 30
153,600
The numbers
Shares they own
153,600
Value on Jun 30, 2026
$5,272,000
about $5 million
Share of their money
0.1%
less than $1 of every $100 · 81st of 85
Price per share on Jun 30
$34.32
Kind
Shares
Also owned by
No other fund we follow
More about Beam Therapeutics ›
The value uses the price on Jun 30, 2026. The fund may have paid a different price.